

NCT02419378 Raw comparison:

Summary:
CHIA has 38 criteria while your personal folder has 48 criteria
Total found criteria: 38/38
Total not Found: 0/38
Total Extra: 10
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Signed informed consent form (ICF)                 │ Signed informed consent form (ICF)                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age 18 to 55 years old (inclusive) as of the date  │ Age 18 to 55 years old (inclusive) as of the date  │
│ the ICF is signed                                  │ the ICF is signed                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Diagnosis of MS according to the McDonald criteria │ Diagnosis of MS according to the McDonald criteria │
│ 2010 and cranial MRI scan demonstrating white      │ 2010 and cranial MRI scan demonstrating white      │
│ matter lesions attributable to MS within 10 years  │ matter lesions attributable to MS within 10 years  │
│ before Screening                                   │ before Screening                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Onset of MS symptoms (as determined by a           │ Onset of MS symptoms (as determined by a           │
│ neurologist either at present or retrospectively)  │ neurologist either at present or retrospectively)  │
│ within 10 years of the date the ICF is signed      │ within 10 years of the date the ICF is signed      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ EDSS score 0 0 to 5 0 (inclusive) at Screening     │ EDSS score 0 0 to 5 0 (inclusive) at Screening     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with (highly) active RRMS disease course  │ Patients with (highly) active RRMS disease course  │
│ indicated to receive alemtuzumab according to the  │ indicated to receive alemtuzumab according to the  │
│ following conditions (at least 1 out of 3          │ following conditions (at least 1 out of 3          │
│ conditions has to be fulfilled) 1 =2 MS relapses   │ conditions has to be fulfilled) 1 ≥2 MS relapses   │
│ within 24 months 2 clinical (=1 relapse) or MRI    │ within 24 months 2 clinical (≥1 relapse) or MRI    │
│ (new gadolinium enhancing lesions) disease         │ (new gadolinium enhancing lesions) disease         │
│ activity under therapy with other diseasemodifying │ activity under therapy with other diseasemodifying │
│ therapies 3 severe relapse with high disease       │ therapies 3 severe relapse with high disease       │
│ activity (=9 T2 hyperintense Lesions and =1        │ activity (≥9 T2 hyperintense Lesions and ≥1        │
│ gadolinium enhancing lesion) on MRI                │ gadolinium enhancing lesion) on MRI                │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Completion of all vaccinations required by the     │ Completion of all vaccinations required by the     │
│ applicable immunization guidelines published by    │ applicable immunization guidelines published by    │
│ "ständige Impfkommission" (STIKO)                  │ "ständige Impfkommission" (STIKO)                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of chickenpox or positive test for         │ History of chickenpox or positive test for         │
│ antibodies against varicella zoster virus (VZV)    │ antibodies against varicella zoster virus (VZV)    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Participation in another clinical trial at present │ Participation in another clinical trial at present │
│ or within 4 weeks of study entry There may be      │ or within 4 weeks of study entry There may be      │
│ exceptions at the discretion of the Investigator   │ exceptions at the discretion of the Investigator   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Has any progressive form of MS                     │ Has any progressive form of MS                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Hypersensitivity to the active substance or to any │ Hypersensitivity to the active substance or to any │
│ of the excipients of Lemtrada®                     │ of the excipients of Lemtrada®                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Medical psychiatric cognitive or other conditions  │ Medical psychiatric cognitive or other conditions  │
│ that in the Investigator's opinion compromise the  │ that in the Investigator's opinion compromise the  │
│ patient's ability to understand the patient        │ patient's ability to understand the patient        │
│ information to give informed consent to comply     │ information to give informed consent to comply     │
│ with the trial protocol or to complete the study   │ with the trial protocol or to complete the study   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any disability acquired from trauma or another     │ Any disability acquired from trauma or another     │
│ illness that could interfere with evaluation of    │ illness that could interfere with evaluation of    │
│ disability due to MS                               │ disability due to MS                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major systemic disease or other illness that would │ Major systemic disease or other illness that would │
│ in the opinion of the Investigator compromise      │ in the opinion of the Investigator compromise      │
│ patient safety or interfere with the               │ patient safety or interfere with the               │
│ interpretation of study results e g current peptic │ interpretation of study results e g current peptic │
│ ulcer disease or other conditions that may         │ ulcer disease or other conditions that may         │
│ predispose to hemorrhage                           │ predispose to hemorrhage                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Known bleeding disorder (e g dysfibrinogenemia     │ Known bleeding disorder (e g dysfibrinogenemia     │
│ factor IX deficiency hemophilia Von Willebrand's   │ factor IX deficiency hemophilia Von Willebrand's   │
│ disease disseminated intravascular coagulation     │ disease disseminated intravascular coagulation     │
│ (DIC) fibrinogen deficiency or clotting factor     │ (DIC) fibrinogen deficiency or clotting factor     │
│ deficiency)                                        │ deficiency)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Significant autoimmune disease including but not   │ Significant autoimmune disease including but not   │
│ limited to immune cytopenias rheumatoid arthritis  │ limited to immune cytopenias rheumatoid arthritis  │
│ systemic lupus erythematosus other connective      │ systemic lupus erythematosus other connective      │
│ tissue disorders vasculitis inflammatory bowel     │ tissue disorders vasculitis inflammatory bowel     │
│ disease severe psoriasis                           │ disease severe psoriasis                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ History of malignancy except basal skin cell       │ History of malignancy except basal skin cell       │
│ carcinoma                                          │ carcinoma                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Major psychiatric disorder that is not adequately  │ Major psychiatric disorder that is not adequately  │
│ controlled by treatment                            │ controlled by treatment                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Epileptic seizures that are not adequately         │ Epileptic seizures that are not adequately         │
│ controlled by Treatment                            │ controlled by Treatment                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active infection e g deep-tissue infection that    │ Active infection e g deep-tissue infection that    │
│ the Investigator considers sufficiently serious to │ the Investigator considers sufficiently serious to │
│ preclude study participation                       │ preclude study participation                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ In the Investigator's opinion is at high risk for  │ In the Investigator's opinion is at high risk for  │
│ infection (e g indwelling catheter dysphagia with  │ infection (e g indwelling catheter dysphagia with  │
│ aspiration decubitus ulcer history of prior        │ aspiration decubitus ulcer history of prior        │
│ aspiration pneumonia or recurrent urinary tract    │ aspiration pneumonia or recurrent urinary tract    │
│ infection)                                         │ infection)                                         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Seropositivity for human immunodeficiency virus    │ Seropositivity for human immunodeficiency virus    │
│ (HIV)                                              │ (HIV)                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Infection with hepatitis C Virus                   │ Infection with hepatitis C Virus                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Past or present hepatitis B infection (positive    │ Past or present hepatitis B infection (positive    │
│ hepatitis B serology)                              │ hepatitis B serology)                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Active infection with human cytomegaly virus       │ Active infection with human cytomegaly virus       │
│ (HCMV) Epstein-Barr virus (EBV) varicella-zoster   │ (HCMV) Epstein-Barr virus (EBV) varicella-zoster   │
│ virus (VZV)                                        │ virus (VZV)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Latent tuberculosis unless effective anti-         │ Latent tuberculosis unless effective anti-         │
│ tuberculosis therapy has been completed or active  │ tuberculosis therapy has been completed or active  │
│ tuberculosis                                       │ tuberculosis                                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Invasive fungal infections in history and at       │ Invasive fungal infections in history and at       │
│ present                                            │ present                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cervical cytology other than PAP I or PAP II       │ Cervical cytology other than PAP I or PAP II       │
│ (Papanicolaou) or cervical high risk human         │ (Papanicolaou) or cervical high risk human         │
│ papillomavirus (HPV) positivity                    │ papillomavirus (HPV) positivity                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Any other illness or infection (latent or active)  │ Any other illness or infection (latent or active)  │
│ that in the Investigator's opinion could be        │ that in the Investigator's opinion could be        │
│ exacerbated by study medication                    │ exacerbated by study medication                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Differential blood count < lower limit of normal   │ Differential blood count \< lower limit of normal  │
│ (LLN) at Screening                                 │ (LLN) at Screening                                 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Confirmed platelet count < the LLN of the          │ Confirmed platelet count \< the LLN of the         │
│ evaluating laboratory at Screening or documented   │ evaluating laboratory at Screening or documented   │
│ at <100 000/µL within the past year on a sample    │ at \<100 000/μL within the past year on a sample   │
│ without platelet clumping                          │ without platelet clumping                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Presence (i e above the ULN) of anti-thyroid       │ Presence (i e above the ULN) of anti-thyroid       │
│ stimulating hormone receptor antibodies (anti-     │ stimulating hormone receptor antibodies (anti-     │
│ TSHR) and anti-thyroid peroxidase antibody (anti-  │ TSHR) and anti-thyroid peroxidase antibody (anti-  │
│ TPO)                                               │ TPO)                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Vaccination less than 6 weeks prior to treatment   │ Vaccination less than 6 weeks prior to treatment   │
│ with Lemtrada                                      │ with Lemtrada                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Treatment with antineoplastic or immunosuppressive │ Treatment with antineoplastic or immunosuppressive │
│ drugs within 8 weeks prior to study inclusion      │ drugs within 8 weeks prior to study inclusion      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Intolerance of pulsed corticosteroids especially a │ Intolerance of pulsed corticosteroids especially a │
│ history of steroid psychosis                       │ history of steroid psychosis                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Inability to undergo MRI with gadolinium           │ Inability to undergo MRI with gadolinium           │
│ administration                                     │ administration                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Of childbearing potential with a positive serum    │ Of childbearing potential with a positive serum    │
│ pregnancy test pregnant or lactating               │ pregnancy test pregnant or lactating               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Female patients of childbearing potential          │ Female patients of childbearing potential          │
│ Unwilling to agree to use a reliable and           │ Unwilling to agree to use a reliable and           │
│ acceptable contraceptive method (Pearl index <1)   │ acceptable contraceptive method (Pearl index \<1)  │
│ throughout the study period These methods include  │ throughout the study period These methods include  │
│ hormone releasing intrauterine device (IUD)        │ hormone releasing intrauterine device (IUD)        │
│ hormonal-based contraception surgical              │ hormonal-based contraception surgical              │
│ sterilization abstinence or double-barrier         │ sterilization abstinence or double-barrier         │
│ contraception (condom and occlusive cap [diaphragm │ contraception (condom and occlusive cap            │
│ or cervical cap combined with spermicide])         │ \[diaphragm or cervical cap combined with          │
│                                                    │ spermicide\])                                      │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                           │
╞═══════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Any hepatic or renal function value grade 2 or higher at Screening with the exception of          │
│ hyperbilirubinemia due to Gilbert's syndrome See Table below drawn from the National Cancer       │
│ Institute (NCI) Common Terminology Criteria for Adverse Events v4 0 (CTCAE) published 28 May 2009 │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have maximum age of 55 Years                                                                 │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Alkaline phosphatase \>2 5 × ULN                                                                  │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ SGPT/ALT \>3 0 × ULN                                                                              │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Creatinine \> 1 5 × ULN                                                                           │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Bilirubin \>1 5 × ULN                                                                             │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ SGOT/AST \>3 0 × ULN                                                                              │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Renal                                                                                             │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Hepatic                                                                                           │
├───────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                 │
╘═══════════════════════════════════════════════════════════════════════════════════════════════════╛